Themes
Business
Talent
At the park
Communities
Jobs & internships
Events
News
Contact
Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme.
The funding will support the clinical development of Leyden Labs’ PanFlu nasal spray, an intranasal antibody therapy designed to protect against a broad range of influenza viruses, including seasonal flu, avian flu (H5), and future respiratory threats. Unlike traditional vaccines, this approach offers direct, fast-acting protection at the site of infection: the respiratory mucosa.
With this investment, Leyden Labs takes a major step forward in preparing for future pandemics through scalable, accessible prevention strategies that complement existing vaccine efforts.
Read more here
The Court of Audit visited LBSP to explore how science and entrepreneurship create public value, with stops at TNO, Peregrion, NTrans, and VarmX sparking discussion on biotech innovation.
Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the next wave of biotech...
At BIO International Convention in Boston, biotech ambition turns into partnership and progress. This year, Leiden Bio Science Park joined the Dutch delegation at the Netherlands...